Sunitinib

Drugs

Volumn 66, Issue 17, 2006, Pages 2255-2266

  Deeks, Emma D ^a   Keating, Gillian M ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CYTOCHROME P450 INHIBITOR; CYTOKINE; DIURETIC AGENT; DRUG METABOLITE; IMATINIB; KETOCONAZOLE; PLACEBO; RIFAMPICIN; SU 012662; SUNITINIB; VASCULOTROPIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANGIOGENESIS; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BLEEDING; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMOPERITONEUM; HUMAN; HYPERAMYLASEMIA; HYPERLIPASEMIA; HYPERNATREMIA; HYPERTENSION; HYPOKALEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; TREATMENT INDICATION; TUMOR BLEEDING; TUMOR GROWTH; TUMOR NECROSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES;

EID: 33845323729     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666170-00007     Document Type: Review

References (37)

1. American Cancer Society. Detailed guide: gastrointestinal stromal tumors [online]. Available from URL: http://www.cancer.org [Accessed 2006 Apr 27]
2. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004 Sep 15; 22 (18): 3813-25
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 Aug 15; 347 (7): 472-80
4. Antonescu CR, Besmer P, Guo T, et al. Aquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005 Jun 1; 11 (11): 4182-90
5. American Cancer Society. Cancer facts and figures 2006 [online]. Available from URL: http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf [Accessed 2006 Apr 27]
6. Cooney MM, Remick SC, Vogelzang NJ. Novel agents for the treatment of advanced kidney cancer. Clin Adv Hematol Oncol 2004 Oct; 2 (10): 664-70
7. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004 Feb 1; 22 (3): 454-63
8. Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationships with clinical variables in sporadic renal cancer. Cancer Res 2006 Feb 15; 66 (4): 2000-11
9. Motzer RJ, Dror Michaelson M, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006 Jan 1; 24 (1): 16-24
10. DePrimo S, Bello C, Smeraglia J, et al. The multitargeted kinase inhibitor sunitinib malate (SU11248): soluble protein biomarkers of pharmacodynamic activity in patients with metastatic renal cell cancer [abstract no. 1452]. EJC Suppl 2005 Oct; 3 (2): 420
11. Suppiah R, Finke J, Rini BI, et al. T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias [abstract no. 2526]. J Clin Oncol 2006 Jun; 24 (18 Suppl.): 106
12. Schoeffski P, Wolter P, Himpe U, et al. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation [abstract no. 3092]. J Clin Oncol 2006; 24 (18 Suppl.): 143
13. Manning WC, Bello CL, Deprimo SE, et al. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor [abstract no. 768 plus oral presentation]. 39th Annual Meeting of the American Society of Clinical Oncology 2003 May 31; Chicago (IL): 192
14. Davis D, Heymach J, McCondkey D, et al. Receptor tyrosine kinase activity and apoptosis in gastrointestinal stromal tumours: a pharmacodynamic analysis of response to sunitinib malate (SU11248) [abstract no. A253 plus poster]. 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2005 Nov 14-18; Philadelphia (PA): 120-1
15. Van Den Abbeele AD, Melenevsky Y, De Vries D, et al. FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate [abstract no. 714]. EJC Suppl 2005 Oct; 3 (2): 202-3
16. Toner GC, Mitchell PL, De Boer R, et al. Phase II study of SU11248 in patients with advanced malignancies incorporating PET imaging [abstract no. B16 plus poster]. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2003 Nov 17-21; Boston (MA)
17. Scott AM, Mitchell P, O'Keefe G, et al. Tumor perfusion as assessed by (oxygen-15)-water PET imaging during treatment with sunitinib malate (SU11248) in patients with advanced malignancies [abstract no. C121 plus poster]. 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadelphia (PA)
18. Rosen L, Mulay M, Long J, et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract no. 765]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL)
19. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006 Jan 1; 24 (1): 25-35
20. Davis DW, Heymach JV, McConkey DJ, et al. Receptor tyrosine kinase activity and apoptosis in gastrointestinal stromal tumours: a pharmacodynamic analysis of response to sunitinib malate (SU11248) therapy [abstract no. 715 ]. EJC Suppl 2005 Oct; 3 (2): 203
21. O'Farrell AM, Deprimo SE, Manning WC, et al. Analysis of biomarkers of SU11248 action in an exploratory study in patients with advanced malignancies [abstract no. 939]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31- Jun 3; Chicago (IL)
22. Center for Drug Evaluation and Research. Sutent (sunitinib) medical review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2006/ 021938_S000_Sutent_MedR.pdf [Accessed 2006 May 10]
23. Center for Drug Evaluation and Research. Sutent (sunitinib) pharmacology review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2006/ 021938_S000_Sutent_PharmR.pdf [Accessed 2006 May 10]
24. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003 Jan; 9 (1): 327-37
25. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003 May; 2 (5): 471-8
26. O'Farrell AM, Abrams TJ, Yuen HA. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003 May 1; 101 (9): 3597-605
27. Pfizer. Sutent prescribing information (PI) [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_sutent.pdf [Accessed 2006 Apr 5]
28. Bello C, Laurie S, Zhou J, et al. Food does not effect the pharmacokinetics of sunitinib malate (SU11248), a multitargeted receptor tyrosine kinase inhibitor, in healthy subjects [abstract no. B175 plus poster]. 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadelphia (PA)
29. Bello C, Houk B, Sherman L, et al. The effect of rifampin on the pharmacokinetics of sunitinib malate (SU11248) in Caucasian and Japanese populations [abstract no. 1485]. EJC Suppl 2005 Oct; 3 (2): 430
30. Washington C, Eli M, Bello C, et al. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects [abstract no. 553]. Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL)
31. Demitri GD, Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38
32. Morgan JA, Demetri GD, Fletcher JA, et al. Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate (SU11248) [abstract no. 1456 plus poster]. 13th European Cancer Conference; 2005 Oct 30-Nov 3; Paris
33. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006 Jun 7; 295 (21): 2516-24
34. Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC) [abstract no. 4522]. J Clin Oncol 2006; 24 (18 Suppl.)
35. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11238) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma [abstract no. LBA3]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl.): 930
36. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006 Nov 7; 145 (9): 660-5
37. European Medicines Agency. Sutent: summary of product characeristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Human/EPAR/ Sutent/Sutent.htm [Accessed 2006 Oct 16]